Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Xetra  >  MorphoSys AG    MOR   DE0006632003

News SummaryMost relevantAll newsSector news 

MORPHOSYS : to Present at Upcoming Investor Conference

share with twitter share with LinkedIn share with facebook
share via e-mail
02/02/2011 | 04:05pm CET

MorphoSys AG / MorphoSys to Present at Upcoming Investor Conference Processed and transmitted by Thomson Reuters. The issuer is solely responsible for the content of this announcement.

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that Chief Executive Officer Dr Simon Moroney will present at the upcoming Société Générale Healthcare and Biotechnology Conference in Paris.


Société Générale Healthcare and Biotechnology Conference
Date: February 9, 2011
Venue: Paris, France
Presenter: Dr. Simon Moroney, CEO of MorphoSys AG


A PDF version of the company presentation is provided at www.morphosys.com:





+++MorphoSys will publish its Full Year 2010 Results on February 24, 2011+++



About MorphoSys:
MorphoSys is an independent biotechnology company that develops novel antibodies for therapeutic, diagnostic and research applications. The Company's HuCAL technology is one of the most powerful methods available for generating fully human antibodies. By successfully applying this and other proprietary technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human health-care. Through its alliances with some of the world's leading pharmaceutical companies, MorphoSys has created a pipeline of more than 60 drug candidates. The Company is expanding its drug pipeline by adding new partnered programs, and by building a portfolio of fully-owned therapeutic antibodies. For its proprietary portfolio, the Company is focused on the areas of oncology and inflammation. Its most advanced program MOR103, a first-in-class, fully human antibody against GM-CSF, is currently being tested in a Phase Ib/IIa trial in rheumatoid arthritis patients. Via its business unit AbD Serotec, MorphoSys is expanding the reach of its technologies in the diagnostics and research markets. MorphoSys is headquartered in Munich, Germany and listed on the Frankfurt Stock Exchange under the symbol "MOR". For further information, visit http://www.morphosys.com/:


HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay® and RapMAT® are registered trademarks of MorphoSys. arYlaTM is a trademark of MorphoSys.



This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.





For more information, please contact:

MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122


Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454


Jessica Kulpi
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332




Press Release:

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: MorphoSys AG via Thomson Reuters ONE


share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on MORPHOSYS AG
12/06 MorphoSys Presents Updated Clinical Data for Blood Cancer Candidate MOR208 in..
12/06 MORPHOSYS : Presents Updated Clinical Results for Anti-CD38 Antibody MOR202 at A..
11/29 MORPHOSYS AG : Publication pursuant to §26 sect.1 WpHG (the German Securities Tr..
11/28 MORPHOSYS : Announces That Its Licensee Janssen Has Submitted a Marketing Author..
11/25 MORPHOSYS AG : Publication pursuant to §26 sect.1 WpHG (the German Securities Tr..
11/22 CORRECTION OF A RELEASE FROM 21.11.2 : 05 CET - MorphoSys AG: Publication pursua..
11/21 MORPHOSYS AG : Publication pursuant to §26 sect.1 WpHG (the German Securities Tr..
11/21 MORPHOSYS AG : Notification of managers`transactions according to article 19 MAR
11/21 MORPHOSYS AG : Notification of managers`transactions according to article 19 MAR
More news
Sector news : Biotechnology & Medical Research - NEC
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
11/30 ACTELION : Rejecting J&J could leave Actelion with 'lot of explaining to do'
11/28 Actelion's ambitious independent-minded CEO will drive up takeover price
11/26DJWHAT'S NEWS : Business & Finance -- WSJ
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
11/22 Morphosys Ag (MPSYY) Investor Presentation - Slideshow
11/08 MorphoSys' (MPSYF) CEO Simon Moroney on Q3 2016 Results - Earnings Call Trans..
11/07 MorphoSys AG reports 9M results
10/04 Allergan Shows It Has Stomach For More GI Dealmaking
09/21 MorphoSys (MPSYY) Presents at Bank of America Merrill Lynch 2016 Global Healt..
Financials (€)
Sales 2016 49,9 M
EBIT 2016 -64,5 M
Net income 2016 -52,9 M
Finance 2016 238 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales 2016 20,3x
EV / Sales 2017 20,3x
Capitalization 1 253 M
More Financials
Duration : Period :
MorphoSys AG Technical Analysis Chart | MOR | DE0006632003 | 4-Traders
Full-screen chart
Technical analysis trends MORPHOSYS AG
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 62,9 €
Spread / Average Target 46%
Consensus details
EPS Revisions
More Estimates Revisions
Simon E. Moroney Chief Executive Officer
Gerald Heinz Möller Chairman-Supervisory Board
Jens Holstein Chief Financial Officer
Marlies Sproll Chief Scientific Officer
Steffen Pohlenz Head-Information Technology
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MORPHOSYS AG-25.45%1 343
CELLTRION, INC.--.--%9 992
LONZA GROUP AG8.34%9 288
More Results